CompletedPhase 2

Cabergoline Versus Calcium Gluconate Infusion in the Prevention of Ovarian Hyperstimulation Syndrome

Egypt170 participantsStarted 2016-10

Plain-language summary

The aim of this study is to compare the efficacy of calcium gluconate infusion versus cabergoline in the prevention of ovarian hyperstimulation syndrome (OHSS) in patients pretreated with GnRH agonist long protocol who are at high risk for OHSS.

Who can participate

Age range18 Years – 37 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients who are stimulated using the long luteal GnRH agonist protocol and at high risk for developing OHSS \[have more than 18 follicles (\> 11mm) and serum estradiol ≥ 3000 pg/ml on the day of HCG administration\]. Exclusion Criteria: * Fibrosis of lung * Swelling or inflammation around the heart or lung * Hypertension * Liver disease * Heart valve disease and allergy to cabergoline or ergot derivatives.

What they're measuring

Moderate or severe ovarian hyperstimulation syndrome

Timeframe: Within 4 weeks of HCG adminstration

Trial details

NCT IDNCT02875587

SponsorAljazeera Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-08

View on ClinicalTrials.gov More OHSS trials